Quantum shares surged 191.2% in three months as strong revenue growth, improving margins and debt elimination bolster its outlook despite supply constraints.
Fintel reports that on October 9, 2026, Baird upgraded their outlook for Humana (NYSE:HUM) (XTRA:HUM) from Neutral to Outperform.Humana Inc., based in the United States, operates primarily within the healthcare industry, focusing on health insurance services. The company manages
Helen of Troy's Q2 earnings surged 33.9%, beating estimates as margins improved on tariff benefits and Home & Outdoor strength, prompting a raised FY27 outlook.
The S&P 500 Index ($SPX ) (SPY ) closed down by -0.47% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.39%. December E-mini S&P futures (ESZ26 ) fell -0.41%, and December E-mini...
CIEN's Openreach deployment of 1.6Tb/s optical technology positions it to capitalize on rising bandwidth demand from AI, data centers, cloud adoption and subsea networks.
SNA's Apollo diagnostic unit delivers a stronger-than-usual launch, boosting independent repair shop demand with advanced features and robust sales momentum.
The S&P 500 Index ($SPX ) (SPY ) closed down by -0.47% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.39%. December E-mini S&P futures (ESZ26 ) fell -0.41%, and December E-mini...
In recent trading, shares of Campbell's Company (Symbol: CPB) have crossed above the average analyst 12-month target price of $19.35, changing hands for $19.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v
In recent trading, shares of APA Corp (Symbol: APA) have crossed above the average analyst 12-month target price of $45.22, changing hands for $45.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, o
In recent trading, shares of Haemonetics Corp. (Symbol: HAE) have crossed above the average analyst 12-month target price of $110.45, changing hands for $119.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v